Filing Details

Elevation Oncology Inc.

(Name of Issuer)

Common stock, par value $0.0001 per share

(Title of Class of Securities)

28623U101

(CUSIP Number)

June 5, 2023

(Date of Event which Requires Filing of this Statement)

SCHEDULE 13G

CUSIP No.

28623U101

1	NAMES OF REPORTING PERSONS
	ExodusPoint Capital Partners GP, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(a)☐
	(b)☒
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER
			0
		6	SHARED VOTING POWER
			1,414,824
		7	SOLE DISPOSITIVE POWER
			0
		8	SHARED DISPOSITIVE POWER
			1,414,824
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	1,414,824
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	5.8%
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	CO

CUSIP No.

28623U101

CUSIP No.

28623U101

1	NAMES OF REPORTING PERSONS
	Hyung Lee
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(a)☐
	(b)☒
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER
			0
		6	SHARED VOTING POWER
			1,414,824
		7	SOLE DISPOSITIVE POWER
			0
		8	SHARED DISPOSITIVE POWER
			1,414,824
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	1,414,824
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	5.8%
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IN

Item 1.

 

Elevation Oncology, Inc.

 

 

888 Seventh Avenue, 12^th Floor, New York, New York 10106

Item 2.

 

This statement is filed by (each, a “Reporting Person” and, collectively, the “Reporting Persons”): (i) ExodusPoint Capital Management, LP (“ExodusPoint Capital Management”) with respect to shares of common stock, par value $0.0001 per share (“Shares”), of the Issuer held by ExodusPoint Partners Master Fund, LP, an investment fund it manages (“ExodusPoint Master Fund”); (ii) ExodusPoint Capital Partners GP, LLC (“ExodusPoint Capital Partners”) with respect to Shares held by ExodusPoint Master Fund; (iii) Michael Gelband (“Mr. Gelband”); and (iv) Hyung Lee (“Mr. Lee”), each with respect to Shares beneficially owned by ExodusPoint Capital Management and ExodusPoint Capital Partners.

 

ExodusPoint Capital Management, ExodusPoint Capital Partners, Mr. Gelband and Mr. Lee have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

 

The address of the principal business office of ExodusPoint Capital Management, ExodusPoint Capital Partners, Mr. Gelband and Mr. Lee is 65 East 55^th Street, New York, NY 10022

 

 

ExodusPoint Capital Management is a Delaware limited partnership. ExodusPoint Capital Partners is a Delaware limited liability company. Mr. Gelband is a United States citizen. Mr. Lee is a United States citizen.

 

Common Stock, par value $0.0001 per share

 

28623U101

 

 

Not applicable.

 

The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on June 8, 2023.

ExodusPoint Capital Management, ExodusPoint Capital Partners, Mr. Gelband and Mr. Lee own directly no Shares. Pursuant to an investment management agreement, ExodusPoint Capital Management maintains investment and voting power with respect to the securities held by ExodusPoint Master Fund. ExodusPoint Capital Partners is the general partner of ExodusPoint Capital Management. Mr. Gelband and Mr. Lee control each of ExodusPoint Capital Management and ExodusPoint Capital Partners.

 

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

 

 

ExodusPoint Master Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.

 

 

See discosure in Item 4 hereof.

 

 

Not applicable

 

 

Not applicable

 

 

By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

EXHIBIT INDEX

Page 9 of 9

---